Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | CCR2 | P41597 | 4/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178265 | 0.91 | ALDH1A1 (0.68) | ALDH1A1ROCK2CCR2ROCK1HTT | |
| SCHEMBL3961183 | 0.91 | CHRM2 (0.50) | ALDH1A1ROCK2CCR2ROCK1HTT | |
| SCHEMBL7514428 | 0.85 | PRMT6 (0.59) | ALDH1A1ROCK2HTTPDCD1CD274 | |
| SCHEMBL3889200 | 0.82 | CYP2D6 (0.49) | ALDH1A1ROCK2CCR2ROCK1DRD2 | |
| SCHEMBL25212788 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CHRM2 | |
| SCHEMBL19710807 | 0.82 | BCHE (0.56) | ALDH1A1DRD4HTTPDCD1CD274 | |
| SCHEMBL29864671 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CHRM2 | |
| SCHEMBL13932969 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HTTPDCD1CD274LTA4H | |
| SCHEMBL10998601 | 0.82 | ACHE (0.53) | ROCK2CCR2ROCK1DRD2DRD4 | |
| SCHEMBL8212538 | 0.82 | BCHE (0.56) | ALDH1A1DRD4HTTPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | ALDH1A1 1481/4885ROCK2 1392/4885CCR2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.